Signatera Looks Deeper
ESMO Recap
WEBINAR
Incorporating a personalized, tumor-informed ctDNA monitoring assay in clinical practice for cancers.
Learn more about:
- Clinical utility for MRD monitoring in Cancers
- Exciting new data on IO applications
Date: December 16, 2020
Sessions: 1:00pm or 7:00pm (SGT)
Dr. Angel Rodriguez, MD
Oncology Medical Director at Natera
ADDITIONAL PRESENTATIONS
Clinical Experience of a Personalized and Tumor-Informed Circulating Tumor DNA Assay for Minimal Residual Disease Detection in Oligometastatic Colorectal Cancer Patients
Presentation #: 81MO
Stacey A. Cohen, MD, PhDUniversity of Washington, Fred Hutchinson Cancer Research Center, USABespoke circulating tumor DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presentation #: 370P
Emma Ococks, MSMRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, United KingdomProspective Observational Study Monitoring Circulating Tumor DNA in Resectable Colorectal Cancer Patients Undergoing Radical Surgery: GALAXY Study in CIRCULATE-Japan
Presentation #: 113TiP
Hiroki Yukami, MDNational Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
Dive Deeper
ctDNA and MRD Testing | Colorectal Cancer Care Tools for Surveillance
VideoSeeing beyond the limit: Detect residual disease and assess treatment response
WhitepaperA personalized, tumor informed approach to detect molecular residual disease with high sensitivity and specificity
Whitepaper